Qingjuan Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9682201/publications.pdf

Version: 2024-02-01

		1040056	1281871	
11	510	9	11	
papers	citations	h-index	g-index	
11	1.1		0.1.0	
11	11	11	913	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget, 2016, 7, 56209-56218.	1.8	92
2	Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncology Reports, 2014, 31, 1863-1870.	2.6	89
3	The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer. Frontiers in Oncology, 2018, 8, 502.	2.8	67
4	CD44 acts through RhoA to regulate YAP signaling. Cellular Signalling, 2014, 26, 2504-2513.	3.6	59
5	The Oncogenic and Tumor Suppressive Functions of the Long Noncoding RNA MALAT1: An Emerging Controversy. Frontiers in Genetics, 2020, 11, 93.	2.3	53
6	Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer. Oncology Letters, 2016, 12, 1361-1366.	1.8	48
7	Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Experimental Cell Research, 2018, 362, 362-369.	2.6	46
8	P-Akt/miR-200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. International Journal of Oncology, 2014, 45, 2430-2438.	3.3	24
9	Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer Cancer Cancer Cancer Management Cancer Cancer Cancer Management Cancer Cancer Cancer Management Cancer Cancer Management Cancer Cancer Management Cancer Cancer Management Cancer Management Cancer Management Cancer Management	1.9	17
10	Long noncoding RNAs as tumorigenic factors and therapeutic targets for renal cell carcinoma. Cancer Cell International, 2021, 21, 110.	4.1	9
11	Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. Oncology Reports, 2014, 32, 1401-1408.	2.6	6